Epidemiologic analysis and antifungal susceptibility of Candida blood isolates in southern Taiwan

Journal of Microbiology, Immunology and Infection

Volumn 38, Issue 3, 2005, Pages 200-210

  Chen, Tun Chieh ^a   Chen, Yen Hsu ^a   Tsai, Jih Jin ^a   Peng, Chien Fang ^b   Lu, Po Liang ^a,b   Chang, Ko ^a   Hsieh, Hsiao Cheng ^a   Chen, Tyen Po ^a  

^a Section of Infectious Diseases   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antifungal agents; Candidiasis; Fungemia; Mortality

Indexed keywords

AMPHOTERICIN B; ANTACID AGENT; C REACTIVE PROTEIN; FLUCONAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; NYSTATIN; STEROID;

ADULT; AGED; ARTICLE; CANCER; CANDIDA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; COHORT ANALYSIS; DRUG SENSITIVITY; FEMALE; FUNGEMIA; FUNGUS ISOLATION; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; NONHUMAN; RETROSPECTIVE STUDY; SEPTIC SHOCK; TAIWAN; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, FUNGAL; FEMALE; FUNGEMIA; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN;

EID: 22244438248     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess of length of stay. Arch Intern Med 1988;148:2642-5.
2. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:147-51.
3. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control 1996;24:380-8.
4. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30.
5. Center for Disease Control. Statistics of communicable diseases and surveillance report in Taiwan area, 2002. Taipei: Center for Disease Control; 2004:40-4.
6. Hsueh PR, Teng LJ, Yang PC, Ho SW, Luh KT. Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole. Microb Drug Resist 2002;8:311-9.
7. Hung CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Nosocomial candidemia in a university hospital in Taiwan. J Formos Med Assoc 1996;95:19-28.
8. Chen YC, Chang SC, Sun CC, Yang LS, Hsieh WC, Luh KT. Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to 1993. Infect Control Hosp Epidemiol 1997;18:369-75.
9. Wu SP, Hwang SW, Hwang KP, Lu PT, Tsai JJ, Lee YW, et al. An analysis of nosocomial candidemia among hospitalized adult patients. Nosocom Infect Control J 2002;12:355-65.
10. Lin CJ, Lu PL, Hwang KP, Tsai JJ, Chen YH, Lee YW, et al. Secular trends of nosocomial infections in a medical center from 1985 to 1996. Nosocom Infect Control J 2000;10:301-12.
11. Pfaller MA, Messer SA, Houston A, Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis 1998;31:289-96.
12. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989;149:2349-53.
13. Uzun O, Anaissie EJ. Predictors of outcome in cancer patients with candidemia. Ann Oncol 2000;11:1517-21.
14. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3:685-702.
15. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003;16:533-7.
16. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89.
17. Yang YL, Cheng HH, Ho YA, Hsiao CF, Lo HJ. Fluconazole resistance rate of Candida species from different regions and hospital types in Taiwan. J Microbiol Immunol Infect 2003;36:187-91.
18. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. In: Olmsted RN, ed. APIC infection control and applied epidemiology: principles and practice. St. Louis: Mosby; 1996:A1-A20.
19. Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995;39:2520-2.
20. Pfaller MA, Messer SA, Karlsson A, Bolmstrom A. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J Clin Microbiol 1998;36:2586-9.
21. Pfaller MA, Messer SA, Houston A, Millis K, Bolmstrom A, Jones RN. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. J Clin Microbiol 2000;38:3715-7.
22. National Committee for Clinical Laboratory Standards. References method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A2. Wayne, PA: NCCLS; 2002.
23. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001;14:643-58.
24. Pfaller MA, Messer SA, Bolmstrom A. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn Microbiol Infect Dis 1998;32:223-7.
25. Clancy CJ, Nguyen MH. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob Agents Chemother 1999;43:1289-90.
26. Chryssanthou E. Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A reference method. J Clin Microbiol 2001;39:4181-3.
27. van Eldere J, Joosten L, Verhaeghe A, Surmont I. Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test. J Clin Microbiol 1996;34:842-7.
28. Nguyen MH, Clancy CJ, Yu VL, Yu YC, Morris AJ, Snydman DR, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998;177:425-30.
29. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002;35:982-9.
30. Kovacicova G, Krupova Y, Lovaszova M, Roidova A, Trupl J, Liskova A, et al. Antifungal susceptibility of 262 blood stream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia? J Infect Chemother 2000;6:216-21.
31. Hospenthal DR, Murray CK, Rinaldi MG. The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis 2004;48:153-60.
32. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997;24:235-47.
33. Wenisch C, Moore CB, Krause R, Presterl E, Pichna P, Denning DW. Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome. J Clin Microbiol 2001;39:2458-62.
34. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother 1995;39:40-4.
35. Lee SC, Fung CP, Huang JS, Tsai CJ, Chen KS, Chen HY, et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 2000;44:2715-8.
36. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001;39:3254-9.
37. Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JJ, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003;82:309-21.
38. Chen YC, Chang SC, Luh KT, Hsieh WC. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003;52:71-7.
39. Shen SH, Jang TN, Huang CS, Lee SH. Nosocomial fungaemia in a medical center in northern Taiwan. Nosocom Infect Control J 2001;11:355-64.
40. Cheng MF, Yu KW, Tang RB, Fan YH, Yang YL, Hsieh KS, et al. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn Microbiol Infect Dis 2004;48:33-7.
41. Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol 2004;25:60-4.
42. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002;50:243-60.
43. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122-8.
44. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-21.
45. Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 1992;14:S120-5.
46. Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002;112:380-5.